

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-53. (Canceled)

Claim 54. (Previously Presented) A peptide comprising

$^{20}\text{Cys-Phe-X}_1\text{-X}_2\text{-X}_3\text{-X}_4\text{-X}_5\text{-X}_6\text{-X}_7\text{-Lys-Val-Arg}^{31}$ (SEQ ID NO: 99)

wherein X_1 is Gln, or Ala; X_2 is Trp or Leu; X_3 is Gln, Lys, Orn, Ala, or Nle; X_4 is Arg, Lys, Ala; X_5 is Asn, Orn, Ala, or Nle; X_6 is Met or Leu; and X_7 is Arg or Lys, and wherein SEQ ID NO: 38 is excluded.

Claim 55. (Previously Presented) The peptide of claim 54, wherein the peptide is SEQ ID NO: 70, 72, 73, 74, 80-83, 87-91, 93-95 or 97.

Claim 56. (Previously Presented) The peptide of claim 54, wherein X_1 is Gln and X_5 is Asn.

Claim 57. (Previously Presented) The peptide of claim 54, wherein the peptide further comprises Gly Pro Pro Val Ser Cys Ile Lys Arg (SEQ ID NO: 101) at the carboxy terminus.

Claim 58. (Previously Presented) The peptide of claim 54, wherein the peptide further comprises Thr Lys or Glu Ala Thr Lys (SEQ ID NO: 102) at the amino terminus of the peptide.

Claim 59. (Previously Presented) The peptide of claim 57, wherein the peptide further comprises Thr Lys or Glu Ala Thr Lys (SEQ ID NO: 102) at the amino terminus of the peptide.

Claim 60. (Previously Presented) The peptide of claim 57, wherein the peptide is cyclised through a disulfide bridge.

Claim 61. (Previously Presented) The peptide of claim 55, wherein the peptide further comprises GPPVSCIKR (SEQ ID NO: 101) at the carboxy terminus.

Claim 62. (Previously Presented) The peptide of claim 55, wherein the peptide further comprises TK or EATK (SEQ ID NO: 102) at the amino terminus of the peptide.

Claim 63. (Previously Presented) The peptide of claim 61, wherein the peptide further comprises TK or EATK (SEQ ID NO: 102) at the amino terminus of the peptide.

Claim 64. (Previously Presented) The peptide of claim 61, wherein the peptide is cyclised through a disulfide bridge.

Claim 65. (Previously Presented) The peptide of claim 54, wherein the N-terminal amino acid of the peptide is acetylated and amidated.

Claim 66. (Previously Presented) The peptide of claim 54, wherein the cysteine is replaced by an acetamidomethyl-cysteine.

Claim 67. (Previously Presented) The peptide of claim 54, wherein the peptide comprises any of SEQ ID NOS: 68-96.

Claim 68. (Currently Amended) The peptide of claim 55, wherein the peptide is comprising SEQ ID NO: 70 or 74.

Claim 69. (Currently Amended) The peptide of claim 55, wherein the peptide is comprising SEQ ID NO: 81 or 83.

Claim 70. (Currently Amended) The peptide of claim 55, wherein the peptide is comprising SEQ ID NO: 87 or 89.

Claim 71. (Currently Amended) The peptide of claim 55, wherein the peptide is comprising SEQ ID NO: 91.

Claim 72. (Previously Presented) A peptide of claim 54, wherein the peptide has a capped C-terminus.

Claim 73. (Previously Presented) The peptide of claim 72, wherein the peptide is SEQ ID NO: 47 or 92.

Claim 74. (Previously Presented) A peptide of claim 72, wherein the peptide further has a capped N-terminus.

Claim 75. (Previously Presented) A medicinal product comprising a peptide of claim 54.

Claim 76. (Previously Presented) A medicinal product comprising a peptide of claim 55.

Claim 77. (Previously Presented) The medicinal product of claim 75 for treatment or prevention of infections or inflammations.

Claim 78. (Previously Presented) The medicinal product of claim 77 for treatment or prevention of a urinary tract infection.

Claim 79. (Previously Presented) The medicinal product of claim 77 for treatment or prevention of colitis.

Claim 80. (Previously Presented) The medicinal product of claim 77 for treatment of a candida infection on a mucosal membrane.

Claim 81. (Previously Presented) The medicinal product of claim 75 formulated for parenteral administration.

Claim 82. (Previously Presented) The medicinal product of claim 75 formulated for oral administration.

Claim 83. (Previously Presented) The medicinal product of claim 75 formulated for topical administration.

Claim 84. (Previously Presented) The medicinal product of claim 83 formulated for administration on mucosal membranes.

Claim 85. (Previously Presented) A food stuff comprising a peptide of claim 54.

Claim 86. (Previously Presented) The food stuff of claim 85, wherein the food stuff is an infant formula food.

Claim 87. (Previously Presented) A method of treating infections or inflammations comprising administering to a patient in need thereof an amount of a peptide of claim 54, wherein the amount of peptide is effective to reduce infections or inflammations.

Claim 88. (Previously Presented) A method of treating infections or inflammations comprising administering to a patient in need thereof an amount of a peptide of claim 55, wherein the amount of peptide is effective to reduce infections or inflammations.

Claim 89. (Previously Presented) The method of claim 87, wherein the infection is an urinary tract infection.

Claim 90. (Previously Presented) The method of claim 87, wherein the inflammation or infection is colitis.

Claim 91. (Previously Presented) The method of claim 87, wherein the infection is a candida infection on a mucosal membrane.

Claim 92. (Previously Presented) The method of claim 87, wherein the peptide is administered orally.

Claim 93. (Previously Presented) The method of claim 87, wherein the peptide is administered parenterally.

Claim 94. (Previously Presented) The method of claim 87, wherein the peptide is administered topically.

Claim 95. (Previously Presented) The method of claim 94, wherein the peptide is administered on mucosal membranes.

Claim 96. (Previously Presented) The method of claim 92, wherein the peptide is administered orally in a food stuff.

Claim 97. (Previously Presented) The method of claim 96, wherein food stuff is an infant formula food.

Claim 98. (Previously Presented) The peptide of claim 54, wherein the N-terminal amino acid of the peptide is acetylated or amidated.